Abbott Laboratories is likely to see its shares rise again after trading range-bound for nearly a year on the back of its $25 billion acquisition of medical device-maker St. Jude Medical, Barron's said on Sunday. The global healthcare company, based in Abbott Park, Illinois, has seen its stock trade between $37 and $45 for a year, as investors remain concerned over currency headwinds given the company's global business and its St. Jude acquisition. The St. Jude deal, which closed last month, has weighed on the stock, with some investors questioning whether Abbott overpaid for a company that's seen a history of delayed product launches.